The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Argus from a “buy” rating to a “hold” rating in a report released on ...

Fintel reports that on April 4, 2025, Argus Research downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

For example the Biogen Inc. (NASDAQ:BIIB) share price dropped 56% over five years. That's an unpleasant experience for long term holders. And it's not just long term holders hurting, because the stock ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Biotechnology company Biogen (BIIB) announced on Monday plans for new headquarters at Kendall Common, located at 75 Broadway ...

Biogen (NasdaqGS:BIIB) recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, ...

Shares of Biogen Inc. BIIB slid 5.91% to $122.98 Friday, on what proved to be an all-around rough trading session for the ...

Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, BIIB080. How Does the Fast Track Tag Benefit BIIB’s Drug Development?

Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to BIIB080, an investigational ...

As previously reported, Argus downgraded Biogen (BIIB) to Hold from Buy. The company has provided guidance for 2025, noting that it expects ...